Dabrafenib plus trametinib can produce durable responses in pediatric patients with relapsed or refractory, BRAFV600-mutant high-grade glioma, a phase 2 trial suggests.
A new study suggests that accounting, hairdressing, sales, and other occupations may be associated with an increased risk of ovarian cancer.
Adding niraparib to first-line treatment with AAP can improve outcomes in patients with mCRPC and HRR alterations, a phase 3 trial suggests.
Adding perioperative nivolumab to neoadjuvant chemotherapy improves outcomes in patients with resectable stage IIIA-B NSCLC, a phase 2 trial suggests.
The CAR T-cell therapy ARI0002h can produce durable responses in patients with relapsed or refractory multiple myeloma, a pilot study suggests.
Neoadjuvant FOLFIRINOX does not provide a survival benefit over upfront surgery in resectable pancreatic cancer, a phase 2 study suggests.
First-line treatment with surufatinib and toripalimab provided disease control in 100% of patients with advanced, PD-L1+ NSCLC.
As many as 1 in 4 patients receiving treatment for cancer and HIV may be at risk of experiencing drug-drug interactions, according to researchers.
The investigational drug VT3989 appears safe and can produce responses in patients with refractory mesothelioma or sarcoma, a phase 1 study suggests.
Combination dabrafenib and trametinib has demonstrated activity against multiple rare cancers harboring the BRAF V600E mutation.
